Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives

三阴性乳腺癌 乳腺癌 肿瘤科 电流(流体) 医学 新辅助治疗 内科学 癌症 工程类 电气工程
作者
Zhenjun Huang,Qing Peng,Luhui Mao,Wenhao Ouyang,Yunjing Xiong,Yujie Tan,Haizhu Chen,Zebang Zhang,Li Tang,Hu Y,Ying Wang,Wei Zhang,Herui Yao,Yunfang Yu
出处
期刊: [Wiley]
卷期号:4 (1) 被引量:4
标识
DOI:10.1002/mef2.70013
摘要

ABSTRACT Triple‐negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, characterized by poor prognosis and limited therapeutic options. Although neoadjuvant chemotherapy (NACT) remains the established treatment approach, its suboptimal efficacy associated with TNBC highlight the urgent need for optimized treatment strategies to improve pathological complete response (pCR) rates. This review provides a comprehensive overview of recent advancements in neoadjuvant treatment for TNBC, emphasizing pivotal breakthroughs in therapeutic strategies and the ongoing pursuit of innovative approaches to enhance precision medicine. It emphasizes the clinical value of platinum‐based agents, such as carboplatin and cisplatin, which have shown significant improvements in pCR rates, particularly in TNBC patients with BRCA mutations. Additionally, the review explores progress in targeted therapies, including PARP inhibitors, AKT inhibitors, and Antiangiogenic agents, showcasing their potential for personalized treatment approaches. The integration of immunotherapy, particularly immune checkpoint inhibitor like pembrolizumab and atezolizumab, with chemotherapy has demonstrated substantial efficacy in high‐risk TNBC cases. Future research priorities include refining biomarker‐driven strategies, optimizing therapeutic combinations, developing antibody‐drug conjugates (ADCs) targeting TROP2 and other biomarkers, and reducing treatment‐related toxicity to develop safer and highly personalized neoadjuvant therapies. Furthermore, artificial intelligence has also emerged as a transformative tool in predicting treatment response and optimizing therapeutic decision‐making in TNBC. These advancements aim to improve long‐term outcomes and quality of life for patients with TNBC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
ayayaya发布了新的文献求助10
1秒前
唐唐发布了新的文献求助10
1秒前
乐观菠萝发布了新的文献求助10
1秒前
作业本的应助被MM采纳,获得10
1秒前
田様的应助被龙金兴采纳,获得10
2秒前
3秒前
3秒前
4秒前
CipherSage的应助被renn采纳,获得10
4秒前
zqy发布了新的文献求助10
5秒前
生动的面包完成签到,获得积分10
5秒前
honey发布了新的文献求助10
7秒前
凯旋888发布了新的文献求助10
7秒前
小二郎的应助被久处采纳,获得30
7秒前
7秒前
kkk发布了新的文献求助10
8秒前
乐超多完成签到,获得积分10
10秒前
10秒前
10秒前
孤独口红完成签到,获得积分10
11秒前
哈哈哈完成签到,获得积分10
11秒前
科研通AI6.3的应助被乐观荔枝采纳,获得10
11秒前
12秒前
奋斗的海豚完成签到 ,获得积分10
12秒前
Jasper的应助被陈陈陈采纳,获得10
13秒前
13秒前
隐形曼青的应助被111采纳,获得10
14秒前
WAO发布了新的文献求助10
16秒前
张豪完成签到,获得积分10
17秒前
18秒前
19秒前
大熊发布了新的文献求助10
19秒前
Jasper的应助被空中马铃薯采纳,获得10
20秒前
英姑的应助被wenhan采纳,获得10
20秒前
SciGPT的应助被唐唐采纳,获得10
21秒前
Lucas的应助被浮生采纳,获得10
21秒前
陈陈陈完成签到,获得积分10
21秒前
856关闭了856的文献求助
21秒前
大橘为重完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184061
求助须知:如何正确求助?哪些是违规求助? 9573151
关于积分的说明 21829878
捐赠科研通 7781058
什么是DOI,文献DOI怎么找? 3434216
关于科研通互助平台的介绍 2558337
邀请新用户注册赠送积分活动 2480674